

Soluble alpha klotho—impact of biological variables and reference intervals for adults

Júnia Ribeiro de Oliveira Longo Schweizer,¹ Katharina Schilbach,^{1,2} Michael Haenelt,¹ Anica Gagliardo,¹ Annette Peters,^{3,4,5} Barbara Thorand,^{3,4} Sylvère Störmann,¹ Jochen Schopohl,¹ Martin Reincke,¹ Michael Lauseker,⁴ and Martin Bidlingmaier^{1,*}

¹Department of Medicine IV, LMU University Hospital, LMU Munich, 80336 Munich, Germany

²Deggendorf Institute of Technology, 94469 Deggendorf, Germany

³Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany

⁴Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), Faculty of Medicine, LMU Munich, Pettenkofer School of Public Health, 81377 Munich, Germany

⁵German Centre for Cardiovascular Research (DZHK), Partner site Munich Heart Alliance, 85764 Munich, Germany

*Corresponding author: Medizinische Klinik und Poliklinik IV, Endocrine Laboratory, Ziemssenstrasse 1, Munich, Bavaria 80336, Germany.

Email: martin.bidlingmaier@med.uni-muenchen.de

Abstract

Objective: Concentrations of soluble alpha klotho (sαKL) are higher in active acromegaly compared with healthy controls. However, reference intervals based on large population-based samples are lacking, and the impact of many biological variables is unclear.

Design: Cross-sectional study

Methods: We measured sαKL concentrations in samples from an adult population (20–89 years, 435 males, 455 females). Associations with sex, age, body mass index, waist-hip-ratio, estimated glomerular filtration rate (eGFR), IGF-I and IGFBP 3, glucose-, lipid-, calcium- and liver-metabolism, fasting, and estrogen status were analyzed. Reference intervals were calculated using LMS quantile regression with a Box-Cox transformation to normality. We also analyzed sαKL in patients with non-functioning pituitary adenoma (NFPA, *n* = 18) and prolactinoma (*n* = 65).

Results: Across all ages, sαKL concentrations (pg/mL, median [interquartile ranges]) were slightly, but significantly higher in females compared with males (678 [537–859] vs. 651 [537–812], *P* = .01), suggesting an impact of estrogens. sαKL exhibited a weak negative correlation with age, and positive correlations with eGFR and IGF-I (*P* < .001 for both). Correlations to other biological factors including glucose, liver and calcium metabolism and duration of fasting were negligible (*P* > .05 for all). Compared with sαKL, IGF-I more often was correlated significantly to other biological variables. sαKL was not different in patients with NFPA, but slightly higher in patients with prolactinoma (*P* < .05).

Conclusion: Our findings suggest sαKL is a stable GH-sensitive biomarker that may be less impacted by biological variables compared with IGF-I and IGFBP 3. Our reference intervals will facilitate the potential use of sαKL in GH-related diseases.

Keywords: biomarker, acromegaly, growth hormone, population-based study

Significance

Soluble alpha klotho (sαKL) concentrations correlated with age and estimated glomerular filtration rate, and might be impacted by estrogen status. However, the impact of other biological variables is negligible, and weaker than that observed for the classical GH-dependent biomarkers IGF-I and IGFBP 3. Our detailed reference intervals for sαKL from a large population-based sample might facilitate its use as a specific GH-sensitive biomarker in GH related diseases.

Introduction

Klotho is a protein first described in mice, where defects in *klotho* gene expression are associated with short lifespan, pituitary abnormalities, growth retardation, and altered calcium and glucose metabolism.¹ *Klotho* is abundantly expressed in the kidney, but expression also occurs in the pituitary.^{1,2} The *Klotho* gene might be a tumor suppressor gene,^{3–6} and encodes a 130-kDa transmembrane protein called alpha klotho. Its extracellular domain contains 2 internal repeats (KL1 and KL2). Three isoforms of alpha klotho exist: the full-

length transmembrane form (mKL), a soluble form consisting of cleaved parts of the extracellular domain (KL1 attached to KL2 [KL1-KL2] or KL1 alone), and a secreted form resulting from alternative splicing and consisting of KL1 only.⁷ While full-length mKL functions as a co-receptor of fibroblast growth factor 23, regulating calcium and phosphorous homeostasis,^{8,9} soluble alpha klotho (sαKL) presumably has endocrine functions. Enzymes from a disintegrin and metalloprotease family (ADAM 10 and 17), as well as β APP converting enzyme 1 (BACE-1) lead to shedding of sαKL. Recent studies suggest an association between klotho and the growth

Received: February 12, 2025. Revised: April 9, 2025. Editorial Decision: April 22, 2025

© The Author(s) 2025. Published by Oxford University Press on behalf of European Society of Endocrinology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

hormone (GH) and insulin-like growth factor I (IGF-I) axis,^{7,10-13} and an association with insulin physiology, suppression of IGF-I receptor phosphorylation and insulin and IGF-I signaling.^{12,14} We and others have shown that concentrations of sαKL are particularly high in patients with active acromegaly, and decrease with disease control.¹⁵⁻¹⁸ This suggests it could be an interesting new biomarker in patients with acromegaly. However, the clinical use of biomarkers requires the availability of reference intervals. In our study, the cutoff for sαKL concentrations to distinguish uncontrolled patients from those with controlled acromegaly or healthy controls was higher than the upper limit of the normal range commonly used for the respective immunoassay. This upper limit was derived from the publication first describing the assay, and is based on a small number of healthy individuals.^{18,19} Until today, no study has established reference intervals for sαKL in a larger group of healthy subjects. In addition, information about the impact of biological variables on its concentrations is scarce,¹⁹⁻²⁴ and limited data are available about assay performance characteristics, and pre-analytical stability.^{19,25}

Here, we provide reference intervals for sαKL based on a large number of samples from well-characterized adults. Measurements were performed after careful evaluation of assay performance and pre-analytical stability. We also provide information about the impact of biological variables on sαKL concentrations compared with their impact on well-established biomarkers of GH action, and report concentrations of sαKL in patients with NFPA and prolactinoma.

Methods

Ethics

Collection of blood samples in the different studies, use of data, and measurement of biochemical parameters were approved by the ethics vote of the Bavarian Medical Association and Ethics Committee of the Faculty of the Ludwig Maximilians University, Munich, Germany (approval numbers: 08064, 06068, 228-16 and 152-10). All participants signed informed consent. All research was conducted in compliance with the Declaration of Helsinki.

Subjects and samples

The reference population is comprised of individuals representative of the background population from which the cases were derived. Ethnic background was not an inclusion criterion, but most participants had Caucasian origin. Blood was collected in the context of 3 different studies, and all studies have been previously described in detail.²⁶⁻²⁹ For the present analysis, we selected a total of 890 samples from adult individuals (20-89 years, 435 males, group A). We excluded pregnant females, and subjects with pituitary, hepatic, or malignant diseases. 64 patients (35 males) had a diagnosis of diabetes type 2, all were controlled (glycated hemoglobin (HbA1c) < 6.5%). Extensive demographic details and laboratory data are provided in [table S1](#). Selection was random, with the exception that we ensured equal representation of males and females, and approximately 120 samples per age decade. 199 serum samples (93 males, age 20-76 years) came from the AcroCut study (Munich, Germany) in healthy volunteers; 574 EDTA plasma samples (283 males, age 32-79 years) from the Cooperative Health Research in the Region of Augsburg study (KORA F4, Augsburg, Germany), and 117

serum samples (58 males, age 80-89 years) from the KORA-Age study. The majority of samples were collected in the morning hours after an overnight fast (>12 h [*n* = 573]). Participants of the KORA-Age study were not requested to be fasting when visiting the study center, but the information on fasting status was recorded (8-12 h (*n* = 27), <8 h (*n* = 113). In the remaining subjects (*n* = 177), information on fasting status was missing.

We also collected serum samples from patients with NFPA (B, *n* = 18, 9 males, 24-87 years) or prolactinoma (C, *n* = 65, 22 males, age 17-82 year, [table S2](#)). All patients were included in the Network of Excellence for Neuroendocrine Tumors Munich, a registry alliance of several academic institutions. No patient had medical history, signs, or symptoms of acromegaly or Cushing.

All samples were stored at −20 °C or below before analysis.

Validation of the analytical method and measurement of soluble alpha klotho

SαKL was measured using the commercially available solid-phase sandwich enzyme-linked immunosorbent assay (ELISA) from Immuno-Biological Laboratories (IBL, Hamburg, Germany). We conducted validation experiments for key performance parameters following CLSI guidelines,^{30,31} and tested stability of sαKL under different collection and storage conditions. Detailed information on the validation experiments is provided in the supplemental data file attached to this article. As a result, while generally following the manufacturer's instructions, we implemented modifications to the assay protocol as described in the results section below.

A subgroup of the samples (32 controls, 22 patients with acromegaly) was also analyzed using another commercially available assay (total alpha-Klotho ELISA, Immundiagnostik (IDK), Bensheim, Germany).

Biological variables

Biological variables expected to be potentially relevant for interpretation of sαKL concentrations were collected: Sex (male/female), age (in years), BMI (kg/m²), waist-hip-ratio, estimated glomerular filtration rate (mL/min/1.73 m²), IGF-I (μg/L) and IGFBP 3 (μg/L) concentrations, parameters of glucose, lipid, liver, and calcium metabolism, and estrogen status (defined as pre-menopausal, post-menopausal, or intake of estrogen containing medication).

Other laboratory assessments

Random GH, IGF-I, and IGFBP 3 were measured using automated chemiluminescence immunoassays (IDS-iSYS CLIA, Immunodiagnostic Systems, Boldon, UK). Extensive characterization of these analytical methods and reference intervals has been published elsewhere.^{26,32,33} Estimated glomerular filtration rate (CKD-EPI 2009), and parameters of glucose, lipid, liver, and calcium metabolism, prolactin, and estradiol concentrations were measured using standard methods.

Statistics

The Kolmogorov Smirnov test was used to confirm the non-Gaussian distribution. Continuous variables are presented using medians and interquartile ranges (IQR). For comparisons between different groups (population-based studies, patients with NFPA or prolactinoma), we used Kruskal–Wallis test

followed by Dunn's multiple comparisons post-test if significant. Correlations between saKL and biological variables were calculated by Spearman's rank correlation for non-parametric variables. *P*-values of <.05 were considered significant. Analyses were performed by GraphPad Prism 9.0 (GraphPad Software, La Jolla, CA, USA).

Age- and sex-adjusted reference intervals were calculated by LMS quantile regression with a Box-Cox transformation to normality.^{34,35} The estimated percentiles for each age and sex category are provided. Multivariate regression including some of the studied biological variables as independent predictors was performed. These analyses were performed using R 4.2.2 (©The R Foundation), ie, the package VGAM.

Results

Assay characteristics, pre-analytical stability, and comparison to another assay

Our validation generally confirmed appropriate analytical performance of the IBL saKL immunoassay when following the manufacturer's protocol. Detailed information is provided in the supplements (text and Figures S1-S5).³⁶ We identified 2 steps in the assay protocol where modifications improved performance:

Following the manufacturer's original protocol, which recommends 1 h incubation, we found acceptable intra-assay variability for repeats done in a row, but if pipetted randomly across assay plates, variability increased significantly. Systematic comparison of 1, 2, and 4 h or overnight incubation revealed that increasing the time beyond 2 h reliably prevents this variability (Figure S2). For logistical reasons we used overnight incubation.

We confirmed good linearity for samples with concentrations below 3000 pg/mL (recovery rate (% mean [range]): 96 [92-107]) but found that samples with concentrations exceeding 3000 pg/mL must be diluted at least 1:4 to allow further dilutions in a linear manner (Figure S3). In the majority of samples from healthy subjects, saKL remains above the limit of quantification even when diluted 1:4. We therefore routinely used 1:4 dilution, and only repeated without dilution the few samples with very low concentrations (*n* = 29).

Pre-analytical stability was excellent (Figure S4), with no significant differences in concentrations observed between samples stored at room temperature for up to 120 h before (whole blood), for up to 72 h after centrifugation (serum), submitted to up to 4 freeze/thaw cycles, or after long-term storage at -20 °C (31 months). SaKL also did not differ between serum and EDTA plasma taken in parallel from the same individual (Figure S5).

Parallel assessment of samples by the immunoassays from IBL and IDK revealed significant disagreement (Figures S6A and 6B), with concentrations measured by IDK approximately 8 times higher compared with IBL in healthy controls, but only 2.4 times higher in patients with acromegaly. Results from both assays correlated only in patients with acromegaly ($r_s = 0.70$, $P = .0003$), and not in healthy controls ($r_s = 0.04$, $P = .83$).

Establishment of reference intervals and comparison to IGF-I and IGFBP 3

Intake of (estrogen containing) oral contraception (OC) or estrogen containing oral medication (OE) was discussed to affect saKL concentrations. For analysis of the impact of

biological variables, and for establishment of reference intervals, we therefore excluded 66 females (56 pre-menopausal, 10 post-menopausal) on OC/OE. We also excluded 6 female patients with prolactinoma on OC/OE before comparing patients with prolactinoma to the reference cohort.

In the remaining subjects from the reference sample (*n* = 824), saKL concentrations (pg/mL, median [IQR]) were slightly, but significantly higher in females compared with males (678 [537-859] vs. 651 [537-812], $P = .01$). In both sexes, saKL was negatively correlated to age, with a decline until the age of 40 years (Figure 1). After the age of 40, concentrations remained unchanged in each sex until old age (89 years), still slightly higher in females (651 [522-824]) vs. 613 [522-751], $P = .04$). Sex-specific reference intervals adjusted for age in 1 year increments are provided in tables S3 (males) and 4 (females).

IGF-I and IGFBP 3 concentrations also differed significantly between age groups. Correlations (r_s [95% confidence interval]) with age were higher for IGF-I ($r_s = -0.58$ [-0.63--0.54], $P < .0001$), but similar for IGFBP 3 ($r_s = -0.31$ [-0.35--0.22], $P < .0001$) as compared with saKL ($r_s = -0.29$ [-0.36--0.24], $P < .0001$, Figure 2). Across all ages, the median (interquartile range [IQR], µg/L) was 115 (88-153) for IGF-I and 3869 (3318-4390) for IGFBP 3. IGF-I was higher in males (117 [92-155]) vs. females (106 [84-131]; $P < .0001$), while IGFBP 3 was higher in females (3925 [3355-4536] vs. 3797 [3156-4536]; $P = .01$). IGF-I correlated with IGFBP 3 ($r_s = 0.46$ [0.40-0.51], $P < .0001$). SaKL correlated with IGF-I ($r_s = 0.31$ [0.26-0.38], $P < .0001$, Figure 3), but not with IGFBP 3 ($P = .56$).

In the Acrocut cohort, we were able to measure GH (µg/L) and prolactin (µU/mL, *n* = 199, 93 males, 106 females [37 females on OE] for both), and estradiol (pg/mL, *n* = 137, 31 males, 106 females [37 females on OE]). There was no statistically significant correlation between saKL (868 [720-1122]) and random GH (1.37 [0.13-4.97], $r_s = 0.12$, $P = .09$). This did not change after removing the 37 females on OE ($r_s = 0.14$, $P = .06$). SaKL correlated with prolactin (*n* = 199, 264 [185-381], $r_s = 0.31$, $P < .0001$ (*n* = 162, $r_s = 0.21$, $P = .0006$, if excluding females on OE) and with estradiol concentrations (*n* = 137, 27.5 [14.4-49.9], $r_s = 0.31$, $P = .0002$). However, correlation to estradiol was no longer significant if females on OE were excluded (*n* = 100, $P = .35$).

Impact of biological variables

SaKL exhibited a weak negative correlation with BMI and waist-hip-ratio ($r_s = -0.13$, and -0.12 [-0.20--0.05], $P < .001$ for both, Figure 4A-B). Total cholesterol concentrations were only available in a subset of participants (*n* = 161), but also showed a weak negative correlation to saKL ($r_s = -0.16$ [-0.29--0.02], $P < .001$, Figure 4C). In contrast, a weak positive correlation was seen to estimated glomerular filtration rate (eGFR, $r_s = 0.25$ [0.18-0.31], $P < .0001$, Figure 4D). We also performed multivariate regression analysis with saKL as the dependent variable, and age, sex, BMI, and eGFR as independent predictors. The effect of eGFR on saKL concentrations remained statistically significant across all models. In contrast, the effect of BMI was no longer detectable once age is included. Age remained a significant predictor in all models.

There was no correlation between saKL and fasting glucose, fasting insulin, hemoglobin A1c, homeostasis model




Figure 1. SaKL concentrations in males (A, $n = 435$) and females not taking estrogen containing OC/OE (B, $n = 389$) from the reference cohort. saKL: soluble alpha klotho.




Figure 2. Correlation of age to saKL concentrations (A), with IGF-I (B) and IGFBP 3 (C) in the reference cohort not taking OC/OE ($n = 824$). saKL: soluble alpha klotho, IGF-I: insulin-like growth factor I, IGFBP 3: insulin-like growth factor binding protein 3. 2A: $r_s = -0.29$ (-0.36 to -0.24), $P < .0001$, 2B: $r_s = -0.58$ (-0.63 to -0.54), $P < .0001$, 2C: $r_s = -0.31$ (-0.35 to -0.22), $P < .0001$.

assessment-estimated insulin resistance, and insulin sensitivity index ($P = .35, 0.07, 0.11, 0.10$, and 0.37 , respectively). SaKL concentrations were not significantly different between individuals fasting for different durations (<8 h [$n = 113$], $8-12$ [$n = 27$] or >12 h [$n = 573$], $P = .06$, Figure 5).

There was no correlation of saKL concentrations to gamma-glutamyl transpeptidase (GGT), alkaline phosphatase, glutamic oxaloacetic transaminase and albumin ($P = .13, .53, .06$, and $.52$, respectively), and negligible correlation to glutamic pyruvic transaminase ($r_s = 0.08$ [$0.01-0.15$], $P = .04$). SaKL did also not correlate with parameters of calcium metabolism (25-OH-vitamin D, calcium, phosphorous, and parathyroid hormone [PTH], $P = .82, .78, .12$, and $.55$, respectively).

IGF-I and IGFBP 3 correlated with more biological variables than saKL. IGF-I concentrations negatively correlated with BMI ($r_s = -0.24$ [-0.30 to -0.18], $P < .0001$), waist-hip-ratio ($r_s = -0.12$ [-0.19 to -0.04], $P = .002$), fasting glucose ($r_s = -0.15$ [-0.22 to -0.06], $P = .0006$), HbA1c ($r_s = -0.25$ [-0.32 to -0.18], $P < .0001$), PTH ($r_s = -0.15$ [-0.22 to -0.07], $P < .0001$) and positively with eGFR ($r_s = 0.27$ [0.20 to 0.34], $P < .0001$), 25-OH-vitamin D ($r_s = 0.12$ [$0.04-0.20$], $P = .002$), calcium ($r_s = 0.15$ [$0.06-0.23$], $P < .0005$) and albumin ($r_s = 0.27$ [$0.20-0.34$], $P < .0001$). IGFBP 3 concentrations negatively correlated with age ($r_s = -0.31$ [-0.35 to -0.22], $P < .0001$), waist-hip-ratio ($r_s = -0.16$ [-0.24 to -0.09], $P < .0001$), HbA1c ($r_s = -0.12$

[-0.19 to -0.04], $P < .002$), PTH ($r_s = -0.21$ [-0.28 to -0.14], $P < .0001$), and positively with HOMA-IR ($r_s = 0.15$ [$0.07-0.24$], $P = .0004$), fasting insulin ($r_s = 0.13$ [$0.06-0.21$], $P = .002$), eGFR ($r_s = 0.29$ [$0.22-0.36$], $P < .0001$), GGT ($r_s = 0.18$ [$0.10-0.25$], $P < .0001$), 25-OH-vitamin D ($r_s = 0.13$ [$0.06-0.21$], $P = .0004$), calcium ($r_s = 0.15$ [$0.06-0.23$], $P = .0004$) and albumin ($r_s = 0.32$ [$0.26-0.40$], $P < .0001$).

Concentrations in patients with other pituitary diseases (NFPA and prolactinoma)

SaKL concentrations (pg/mL, median IQR) were not different between the population-based sample (A: 667 [537-836]) and patients with NFPA (B: 755 [676-906]; A vs. B, $P = .09$), but were significantly higher (though within the reference interval) in patients with prolactinoma (904 [759-1283]; A vs. C, $P < .0001$, Figure 6). Notably, in our cohorts, mean (IQR) of IGF-I and IGFBP 3 were within the respective reference intervals for age and sex in patients with both, NFPA and prolactinoma (NFPA: IGF-I: 115 [86.5-161.5], IGFBP 3: 3426 [2829-3536], prolactinoma: IGF-I: 144 [105-193], IGFBP 3: 3694 [3214-4199]).

Impact of estrogen status

To investigate a potential influence of estrogen status, we compared saKL in the studies included in the above analyses




Figure 3. Correlation of sαKL with IGF-I (A) and IGFBP 3 concentrations (B) or IGF-I to IGFBP 3 concentrations (C) in subjects from reference sample not taking OC/OE ($n = 824$). sαKL, soluble alpha klotho; IGF-I, insulin-like growth factor I; IGFBP 3, insulin-like growth factor binding protein 3. 3A, $r_s = 0.31$ (0.26-0.38), $P < .0001$; 3B, $P = .56$; 3C, $r_s = 0.46$ (0.40-0.51), $P < .0001$.




Figure 4. Correlation of sαKL concentrations to BMI (A), waist-hip-ratio (B), total cholesterol concentrations (C), and eGFR (D) in subjects from the reference sample not taking OC/OE ($n = 824$, data for cholesterol, $n = 161$). sαKL, soluble alpha klotho; BMI, body mass index (BMI); eGFR, estimated glomerular filtration rate. 4A, $r_s = -0.13$ (−0.20 to −0.06), $P < .001$; 4B, -0.12 (−0.20 to −0.05), $P < .001$; 4C, $r_s = -0.16$ (−0.29 to −0.02), $P < .001$; 4D, $r_s = 0.25$ (0.18-0.31), $P < .0001$.

(pre- [$n = 158$] and post-menopausal [$n = 231$] females without OE and males [$n = 435$]) to concentrations found in premenopausal females with estrogen containing OC ($n = 56$, Figure 7), and post-menopausal females on OE ($n = 10$). In premenopausal females, sαKL concentrations were not statistically different between individuals with or without OC (716 [639-939] vs. 687 [556-959]; $P = .72$), but the small group of post-menopausal females on OE (492 [316-703]) had lower sαKL compared with post-menopausal females without OE (668 [535-837], $P = .04$). As mentioned above, sαKL concentrations were slightly higher for females when analyzing the whole reference sample (without individuals on OC/OE). However, we found no difference in sαKL between the subgroups of premenopausal females (independent of estrogen status) and males < 50 years (726 [582-891], $P = .80$), and between post-menopausal females with OE and males > 50 years (600 [506-748], $P = .42$). Only in the group of post-menopausal females without OE, sαKL concentrations were

slightly but significantly higher when compared with males > 50 years (600 [506-748], $P = .02$).

In female patients with prolactinoma, sαKL was higher in the patients without OC/OE ($n = 37$, 970 [798-1452]) compared with the few patients receiving OC/OE ($n = 6$, 690 [645-864], $P = .02$). However, sαKL was not different between any of the female patient groups (with or without OC/OE) compared with male patients ($P = .12$ and $.49$, respectively). In patients with NFPA (9 males/9 females) sαKL tended to be lower in males, but the difference did not reach statistical significance (males: 708 [285-891] vs. females: 890 [715-1092], $P = .06$).

Discussion

The primary goal of our study was to establish age- and sex-adjusted reference intervals for sαKL, a protein which we and others recently had proposed as a new biomarker in




Figure 5. sαKL concentrations in individuals fasting < 8 h ($n = 113$), 8–12 h ($n = 27$) or > 12 h ($n = 573$). sαKL: soluble alpha klotho. $P > .05$.

patients with acromegaly.^{15–18,37–39} We first evaluated and optimized performance characteristics of a widely used ELISA, and studied pre-analytical stability of sαKL. We then measured sαKL concentrations in a large sample from the background-population, equally representing sexes and adult age groups. Detailed reference intervals were constructed, and the potential impact of different biological variables was analyzed. Finally, we compared sαKL concentrations obtained in our reference population to concentrations measured in patients with pituitary tumors other than somatotroph adenomas (namely NFPA and prolactinoma).

The sαKL assay used in our study (IBL ELISA) exhibited adequate analytical performance, but we found that 2 modifications to the manufacturers protocol were important: First, extending the initial incubation step from 1 h to overnight significantly improved reproducibility of the measurements within a plate, leading to better within- and between-assay coefficients of variation. Second, while the assay exhibits acceptable linearity across the concentration range seen in healthy subjects, we suggest diluting all samples at least 1:4. The reason is that the standard curve shows a plateau at concentrations exceeding 3000 pg/mL, potentially compromising accuracy at higher concentrations if samples are not adequately diluted. This is important particularly in patients with active acromegaly where sαKL can be very high.

We confirm sαKL concentrations do not differ between paired serum and EDTA plasma samples from the same individual,⁴⁰ and demonstrate pre-analytical robustness under different conditions for collection and storage. Parallel measurements with




Figure 6. sαKL concentrations in individuals from the reference sample ($n = 824$), in patients with NFPA ($n = 18$) and in patients with prolactinoma ($n = 59$). The 3 groups only include individuals not taking OC/OE. sαKL, soluble alpha klotho, NFPA, non-functioning pituitary tumor. **** $P < .0001$.

another commercially available klotho assay (IDK) revealed that results for the same sample disagree dramatically, confirming observations from previous studies using different assays.^{21,40} We found less disagreement in patients with acromegaly compared with healthy controls, suggesting differences in sensitivity might play a role. Other possible explanations include the use of different standards for calibration, and the fact that different assays might recognize different isoforms of sαKL. Future studies are needed to better address this issue, but our observation emphasizes that only results from studies using the same sαKL assay can be compared.

We established reference intervals for the sαKL assay most widely used in the current literature, reflecting age- and sex-related changes in concentrations. While our study population was much larger than previously published studies using the same assay,^{19,21,22,41} sαKL concentrations were in the same order of magnitude. Notably, the upper limits of the normal range for males and females in our study are higher than the upper limit initially reported by Yamazaki et al.¹⁹ Moreover, in our study variation of sαKL concentrations within each age group was greater in females compared with males. Interestingly, this was primarily driven by an upward shift of the 97.5th percentile, while the 2.5th percentiles were comparable between sexes. Since our population mostly consists of individuals with Caucasian background, we cannot exclude an impact of ethnicity. More likely, the difference in cohort size might also play a role. It is intriguing that overall the upper limits of the normal range derived from our study are very close to the cutoff we previously found to best differentiate patients with active acromegaly from those with controlled disease, NFPA or healthy controls.¹⁸ We did not find systematic




Figure 7. sαKL concentrations in pre-menopausal females without OC ($n = 158$), pre-menopausal females with OC ($n = 56$), post-menopausal females without OE ($n = 231$) and males ($n = 435$). sαKL: soluble alpha klotho. * $P < .05$.

differences in sαKL concentrations between males and females with acromegaly in our previous study,¹⁸ but another study had reported this.⁴² Our new data suggest it might be particularly important to use sex-specific upper limits of the normal range for interpretation of sαKL in patients with acromegaly.

Other than in patients with active acromegaly, in the background population sαKL showed only modest correlation with IGF-I, and not with IGFBP 3. Furthermore, the correlation with age for sαKL was weaker than that seen for IGF-I and IGFBP 3. Therefore, while associated with the GH-IGF-I axis to some degree, sαKL concentrations seem to be regulated differently. It has been shown that the enzymes ADAM 10 and 17 induce shedding of sαKL, and GH and IGF-I have been suggested to be involved in regulation of the expression of these enzymes.^{7,10-12} We speculate that this indirect link, modified by other factors, explains the comparably weak association between sαKL and the GH-IGF-I axis under physiological conditions. At the same time, none of the factors analyzed in our study was associated with an increase of sαKL concentrations similar to that seen in active acromegaly.^{16-18,39} This indicates a specific effect of excess GH concentrations on sαKL, supporting its use as a biomarker of disease activity in acromegaly. While the half-life of sαKL has only been described in animal studies, 1 study in patients with acromegaly describes a rapid decrease in sαKL concentrations within 2-6 days after successful pituitary surgery¹⁷ which would be faster than the occurrence of normalization of IGF-I.⁴³

sαKL exhibited a weak negative correlation with the variables age, BMI, waist-hip-ratio and total cholesterol and a

positive correlation with eGFR when variables were considered individually. Since the variables might be correlated among each other, we also performed multivariate analysis. While the correlation of sαKL with eGFR remained significant, the association with BMI disappeared, indicating it was mainly an effect of age. The correlations of sαKL with age and eGFR were already shown in the literature.^{19,44,45} Total cholesterol data were only available for a subset of our cohort, and further studies might be needed to understand a potential association with sαKL.

In our study, we did not observe correlations of sαKL with parameters of glucose metabolism. However, most individuals had normal glucose metabolism. Data in patients with diabetes are controversial, but some studies reported an impact of glucose metabolism on sαKL. Inclusion of patients with kidney diseases in some studies might have contributed to that observation.^{46,47}

Concentrations of prolactin ($n = 199$) and estradiol ($n = 137$) were available only in a small subset of our cohort. sαKL correlated weakly to prolactin in all subjects, but to estradiol only in the all participants (including males and females on OE). The limited number of subjects is a limitation here, and further studies are necessary to clarify the potential impact of those hormones on sαKL concentrations.

We also did not find a correlation of sαKL with parameters of calcium metabolism, mirroring results from our previous study in patients with acromegaly.¹⁸ Some studies had reported correlations between sαKL and parameters of calcium

metabolism in patients with kidney insufficiency.⁴⁸⁻⁵¹ However, in these patients, the transmembrane form of klotho is more relevant. In contrast, shedding and generation of sKl is considered to be largely independent from calcium metabolism.

In patients with NFPA, sKl was comparable to the background population. In contrast, concentrations tended to be slightly higher in patients with prolactinoma. We assume this is due to the younger age, and the higher proportion of females among patients with prolactinoma. We acknowledge that the NFPA group is small ($n = 18$), limiting the statistical power of a comparison. However, the absence of an obvious difference in sKl concentrations in these patient groups to the background population seems to suggest that grossly elevated concentrations of sKl as reported from patients with active acromegaly are not related to a pituitary tumor itself. Notably, in our study, patients with NFPA and prolactinoma all presented with IGF-I and IGFBP 3 concentrations within the reference interval for age and sex. We acknowledge that, although IGF-I concentrations were not different between patients with prolactinoma and NFPA, most of the patients with prolactinoma in our study were not operated. Therefore, we cannot exclude a co-expression of prolactin and GH, potentially explaining the slightly higher mean sKl concentrations in this group.

In our study populations, estrogen status was not correlated with circulating sKl concentrations. Generally, concentrations in all pre- and post-menopausal females without OC/OE were slightly higher compared with concentrations in all males. The small difference remained significant until advanced age. On the other hand, we found no difference in sKl between pre-menopausal females with or without OC use. This is an important difference in the regulation compared with IGF-I, where several studies have shown that oral estrogens induce a state of hepatic GH resistance, leading to reduced IGF-I concentrations.⁵²⁻⁵⁴ Only in the small groups of post-menopausal females with OE or female patients with prolactinoma with OE/OC, concentrations of sKl were lower compared with the concentrations seen in the respective individuals without OE/OC. However, caution is needed in interpretation due to the limited size of the groups ($n = 10$ and $n = 6$, respectively). The absence of a difference in sKl between the large groups of pre-menopausal females with and without OC suggests negligible influence of oral estrogens. A likely explanation is that hepatic expression—contributing to the majority of circulating IGF-I—is less relevant for sKl. Recent reports suggested that anorexia, another condition associated with GH-resistance and low IGF-I, might also be associated with low sKl concentrations.^{55,56} Further studies are needed to understand the significance of and potential mechanisms behind this association.

In summary our findings support the concept that sKl is a highly stable biomarker. The fact that it was specifically elevated in conditions of excess GH secretion, but less related to biological variables compared with IGF-I or IGFBP 3 suggest it might be an interesting new biomarker of disease activity in acromegaly. The reference intervals provided by our study might facilitate the use of sKl as a biomarker in studies and clinical practice.

Supplementary material

[Supplementary material](#) is available at *European Journal of Endocrinology* online.

Funding

This study was supported by a Grant for Growth Innovation (GGI) 2020 from Merck Healthcare KGA, Darmstadt, Germany and by a grant (120000R319) from Partnership for Clean Competition (PCC), Colorado, USA.

The KORA study was initiated and financed by the Helmholtz Zentrum München—German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Data collection in the KORA study is done in cooperation with the University Hospital of Augsburg. The KORA-Age project was financed by the German Federal Ministry of Education and Research (BMBF FKZ 01ET0713 and 01ET1003A) as part of the “Health in old age” program.

Conflict of interest: None declared.

Authors' contributions

Júnia R.O.L. Schweizer (Conceptualization [equal], Data curation [equal], Formal analysis [lead], Investigation [lead], Methodology [equal], Project administration [equal], Validation [equal], Visualization [equal], Writing—original draft [lead], Writing—review & editing [lead]), Katharina Schilbach (Conceptualization [equal], Data curation [equal], Investigation [equal], Methodology [equal], Resources [equal], Writing—review & editing [equal]), Michael Haenelt (Data curation [equal], Formal analysis [equal], Investigation [equal], Methodology [equal], Software [equal], Writing—review & editing [equal]), Anica Gagliardo (Data curation [equal], Investigation [equal], Methodology [equal], Resources [equal], Writing—review & editing [equal]), Annette Peters (Data curation [equal], Funding acquisition [equal], Project administration [equal], Resources [equal], Writing—review & editing [equal]), Barbara Thorand (Data curation [equal], Formal analysis [equal], Methodology [equal], Project administration [equal], Resources [equal], Software [equal], Writing—review & editing [equal]), Sylvere Störmann (Data curation [equal], Investigation [equal], Resources [equal], Writing—review & editing [equal]), Jochen Schopohl (Data curation [equal], Investigation [equal], Project administration [equal], Resources [equal], Writing—review & editing [equal]), Martin Reincke (Funding acquisition [equal], Investigation [equal], Project administration [equal], Resources [equal], Supervision [equal], Writing—review & editing [equal]), Michael Lauseker (Data curation [equal], Formal analysis [equal], Methodology [equal], Software [equal], Visualization [equal], Writing—review & editing [equal]), Martin Bidlingmaier (Conceptualization [lead], Data curation [equal], Formal analysis [equal], Funding acquisition [lead], Investigation [lead], Methodology [equal], Project administration [equal], Resources [lead], Software [equal], Supervision [lead], Validation [equal], Visualization [equal], Writing [lead], and—original draft [equal], Writing—review & editing [lead]).

Data availability

The data underlying this article are presented in the article and in its online [material](#), or are available from the authors upon reasonable request.

References

- Kuro-o M, Matsumura Y, Aizawa H, *et al.* Mutation of the mouse klotho gene leads to a syndrome resembling ageing. *Nature*. 1997;390(6655):45-51. <https://doi.org/10.1038/36285>
- Olauson H, Mencke H, Hillebrands JL, Larsson TE. Tissue expression and source of circulating alphaKlotho. *Bone*. 2017;100:19-35. <https://doi.org/10.1016/j.bone.2017.03.043>
- Sun H, Gao Y, Lu K, *et al.* Overexpression of Klotho suppresses liver cancer progression and induces cell apoptosis by negatively regulating wnt/beta-catenin signaling pathway. *World J Surg Oncol*. 2015;13(1):307. <https://doi.org/10.1186/s12957-015-0717-0>
- Zhu Y, Xu L, Zhang J, *et al.* Klotho suppresses tumor progression via inhibiting PI3K/Akt/GSK3beta/Snail signaling in renal cell carcinoma. *Cancer Sci*. 2013;104(6):663-671. <https://doi.org/10.1111/cas.12134>
- Xie B, Zhou J, Shu G, *et al.* Restoration of klotho gene expression induces apoptosis and autophagy in gastric cancer cells: tumor suppressive role of klotho in gastric cancer. *Cancer Cell Int*. 2013;13(1):18. <https://doi.org/10.1186/1475-2867-13-18>
- Wang Y, Chen L, Huang G, *et al.* Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway. *PLoS One*. 2013;8(2):e57391. <https://doi.org/10.1371/journal.pone.0057391>
- van Loon EPM, Pulsken WP, van der Hagen EAE, *et al.* Shedding of klotho by ADAMs in the kidney. *Am J Physiol Renal Physiol*. 2015;309(4):F359-F368. <https://doi.org/10.1152/ajprenal.00240.2014>
- Razzaque MS. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. *Nat Rev Endocrinol*. 2009;5(11):611-619. <https://doi.org/10.1038/nrendo.2009.196>
- Dalton GD, Xie J, An SW, Huang CL. New insights into the mechanism of action of soluble Klotho. *Front Endocrinol (Lausanne)*. 2017;8:323. <https://doi.org/10.3389/fendo.2017.00323>
- Shahmoon S, Rubinfeld H, Wolf I, *et al.* The aging suppressor klotho: a potential regulator of growth hormone secretion. *Am J Physiol Endocrinol Metab*. 2014;307(3):E326-E334. <https://doi.org/10.1152/ajpendo.00090.2014>
- Hasannejad M, Samsamshariat SZ, Esmaili A, Jahanian-Najafabadi A. Klotho induces insulin resistance possibly through interference with GLUT4 translocation and activation of Akt, GSK3beta, and PFKfbeta3 in 3T3-L1 adipocyte cells. *Res Pharm Sci*. 2019;14(4):369-377. <https://doi.org/10.4103/1735-5362.263627>
- Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. *Proc Natl Acad Sci U S A*. 2007;104(50):19796-19801. <https://doi.org/10.1073/pnas.0709805104>
- Rubinek T, Shahmoon S, Shabtay-Orbach A, *et al.* Klotho response to treatment with growth hormone and the role of IGF-I as a mediator. *Metabolism*. 2016;65(11):1597-1604. <https://doi.org/10.1016/j.metabol.2016.08.004>
- Efthymiadou A, Kritikou D, Mantagos S, Chrysis D. The effect of GH treatment on serum FGF23 and Klotho in GH-deficient children. *Eur J Endocrinol*. 2016;174(4):473-479. <https://doi.org/10.1530/EJE-15-1018>
- Schweizer JROL, Schilbach K, Haenelt M, *et al.* Soluble alpha klotho in acromegaly: Comparison to traditional markers of disease activity. Supplemental material. Posted March 3, 2021. figshare. doi:10.6084/m9.figshare.13614083.
- Coopmans EC, El-Sayed N, Frystyk J, *et al.* Soluble Klotho: a possible predictor of quality of life in acromegaly patients. *Endocrine*. 2020;69(1):165-174. <https://doi.org/10.1007/s12020-020-02306-4>
- Neidert MC, Sze L, Zwimpfer C, *et al.* Soluble alpha-klotho: a novel serum biomarker for the activity of GH-producing pituitary adenomas. *Eur J Endocrinol*. 2013;168(4):575-583. <https://doi.org/10.1530/EJE-12-1045>
- Schweizer JROL, Schilbach K, Haenelt M, *et al.* Soluble alpha klotho in acromegaly: comparison to traditional markers of disease activity. *J Clin Endocrinol Metab*. 2021;106(8):e2887-e2899. <https://doi.org/10.1210/clinem/dgab257>
- Yamazaki Y, Imura A, Urakawa I, *et al.* Establishment of sandwich ELISA for soluble alpha-Klotho measurement: age-dependent change of soluble alpha-Klotho levels in healthy subjects. *Biochem Biophys Res Commun*. 2010;398(3):513-518. <https://doi.org/10.1016/j.bbrc.2010.06.110>
- Semba RD, Cappola AR, Sun K, *et al.* Plasma klotho and mortality risk in older community-dwelling adults. *J Gerontol A Biol Sci Med Sci*. 2011;66(7):794-800. <https://doi.org/10.1093/gerona/gle058>
- Pedersen L, Pedersen SM, Brasen CL, Rasmussen LM. Soluble serum Klotho levels in healthy subjects. Comparison of two different immunoassays. *Clin Biochem*. 2013;46(12):1079-1083. <https://doi.org/10.1016/j.clinbiochem.2013.05.046>
- Verde Z, Gonzalez-Moro JM, Chicharro LM, *et al.* A paradox: alpha-Klotho levels and smoking intensity. *Lung*. 2017;195(1):53-57. <https://doi.org/10.1007/s00408-016-9944-6>
- Zhang Z, Qiu S, Huang X, *et al.* Association between testosterone and serum soluble alpha-klotho in U.S. Males: a cross-sectional study. *BMC Geriatr*. 2022;22(1):570. <https://doi.org/10.1186/s12877-022-03265-3>
- Espuch-Oliver A, Vazquez-Lorente H, Jurado-Fasoli L, *et al.* References values of soluble alpha-Klotho Serum levels using an enzyme-linked immunosorbent assay in healthy adults aged 18-85 years. *J Clin Med*. 2022;11(9):2415. <https://doi.org/10.3390/jcm11092415>
- Tan SJ, Smith ER, Hewitson TD, Holt SG, Toussaint ND. Diurnal variation and short-term pre-analytical stability of serum soluble alpha-klotho in healthy volunteers: a pilot study. *Ann Clin Biochem*. 2015;52(4):506-509. <https://doi.org/10.1177/0004563214563415>
- Bidlingmaier M, Friedrich N, Emeny RT, *et al.* Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. *J Clin Endocrinol Metab*. 2014;99(5):1712-1721. <https://doi.org/10.1210/jc.2013-3059>
- Schilbach K, Gar C, Lechner A, *et al.* Determinants of the growth hormone nadir during oral glucose tolerance test in adults. *Eur J Endocrinol*. 2019;181(1):55-67. <https://doi.org/10.1530/EJE-19-0139>
- Meisinger C, Ruckert IM, Rathmann W, *et al.* Retinol-binding protein 4 is associated with prediabetes in adults from the general population: the Cooperative Health Research in the Region of Augsburg (KORA) F4 study. *Diabetes Care*. 2011;34(7):1648-1650. <https://doi.org/10.2337/dc11-0118>
- Peters A, Doring A, Ladwig KH, *et al.* Multimorbidity and successful aging: the population-based KORA-Age study. *Z Gerontol Geriatr*. 2011;44 Suppl 2(S2):41-54. <https://doi.org/10.1007/s00391-011-0245-7>
- CLSI. *Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline—Third Edition*. CLSI Document EPOS-A3. Wayne, PA: Clinical and Laboratory Standards institute; 2014.
- CLSI. *Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline—Second Edition*. CLSI Document EP17-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
- Manolopoulou J, Alami Y, Petersenn S, *et al.* Automated 22-kD growth hormone-specific assay without interference from pegvisomant. *Clin Chem*. 2012;58(10):1446-1456. <https://doi.org/10.1373/clinchem.2012.188128>
- Friedrich N, Wolthers OD, Arafat AM, *et al.* Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays. *J Clin Endocrinol Metab*. 2014;99(5):1675-1686. <https://doi.org/10.1210/jc.2013-3060>

34. Yee TW. Quantile regression via vector generalized additive models. *Stat Med.* 2004;23(14):2295-2315. <https://doi.org/10.1002/sim.1822>
35. Cole TJ, Green PJ. Smoothing reference centile curves: the LMS method and penalized likelihood. *Stat Med.* 1992;11(10):1305-1319. <https://doi.org/10.1002/sim.4780111005>
36. Schweizer JROL, Schilbach K, Haenelt M, et al. Soluble alpha klotho —impact of biological variables and reference intervals for adults— Supplemental File 2005. <https://doi.org/10.6084/m9.figshare.28730453>
37. Jawiarczyk-Przybyłowska A, Halupczok-Zyla J, Bolanowski M. Soluble alpha-Klotho—a new marker of acromegaly? *Endokrynol Pol.* 2016;67(4):390-396. <https://doi.org/10.5603/EP.a2016.0048>
38. Varewijck AJ, van der Lely AJ, Neggers SJ, Lamberts SWJ, Hofland LJ, Janssen JAMJL. In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life. *Endocr Connect.* 2014;3(2):85-92. <https://doi.org/10.1530/EC-14-0028>
39. Sze L, Bernays RL, Zwimpfer C, Wiesli P, Brandl M, Schmid C. Excessively high soluble Klotho in patients with acromegaly. *J Intern Med.* 2012;272(1):93-97. <https://doi.org/10.1111/j.1365-2796.2012.02542.x>
40. Heijboer AC, Blankenstein MA, Hoenderop J, de Borst MH, Vervloet MG, NIGRAM Consortium. Laboratory aspects of circulating alpha-Klotho. *Nephrol Dial Transplant.* 2013;28(9):2283-2287. <https://doi.org/10.1093/ndt/gft236>
41. Semba RD, Cappola AR, Sun K, et al. Plasma klotho and cardiovascular disease in adults. *J Am Geriatr Soc.* 2011;59(9):1596-1601. <https://doi.org/10.1111/j.1532-5415.2011.03558.x>
42. Sze L, Neidert MC, Bernays RL, et al. Gender dependence of serum soluble Klotho in acromegaly. *Clin Endocrinol (Oxf).* 2014;80(6):869-873. <https://doi.org/10.1111/cen.12385>
43. Feelders RA, Bidlingmaier M, Strasburger CJ, et al. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. *J Clin Endocrinol Metab.* 2005;90(12):6480-6489. <https://doi.org/10.1210/jc.2005-0901>
44. Crasto CL, Semba RD, Sun K, Cappola AR, Bandinelli S, Ferrucci L. Relationship of low-circulating “anti-aging” klotho hormone with disability in activities of daily living among older community-dwelling adults. *Rejuvenation Res.* 2012;15(3):295-301. <https://doi.org/10.1089/rej.2011.1268>
45. Amitani M, Asakawa A, Amitani H, et al. Plasma klotho levels decrease in both anorexia nervosa and obesity. *Nutrition.* 2013;29(9):1106-1109. <https://doi.org/10.1016/j.nut.2013.02.005>
46. van Ark J, Hammes HP, van Dijk MCRF, et al. Circulating alpha-klotho levels are not disturbed in patients with type 2 diabetes with and without macrovascular disease in the absence of nephropathy. *Cardiovasc Diabetol.* 2013;12(1):116. <https://doi.org/10.1186/1475-2840-12-116>
47. Kacso IM, Bondor CI, Kacso G. Soluble serum Klotho in diabetic nephropathy: relationship to VEGF-A. *Clin Biochem.* 2012;45(16-17):1415-1420. <https://doi.org/10.1016/j.clinbiochem.2012.07.098>
48. Zhang Y, Zhao C, Zhang H, et al. Association between serum soluble alpha-klotho and bone mineral density (BMD) in middle-aged and older adults in the United States: a population-based cross-sectional study. *Aging Clin Exp Res.* 2023;35(10):2039-2049. <https://doi.org/10.1007/s40520-023-02483-y>
49. Wang Q, Su W, Shen Z, Wang R. Correlation between soluble alpha-Klotho and renal function in patients with chronic kidney disease: a review and meta-analysis. *Biomed Res Int.* 2018;2018:9481475. <https://doi.org/10.1155/2018/9481475>
50. Rotondi S, Pasquali M, Tartaglione L, et al. Soluble alpha-Klotho Serum levels in chronic kidney disease. *Int J Endocrinol.* 2015;2015:872193. <https://doi.org/10.1155/2015/872193>
51. Pavik I, Jaeger P, Ebner L, et al. Secreted Klotho and FGF23 in chronic kidney disease stage 1 to 5: a sequence suggested from a cross-sectional study. *Nephrol Dial Transplant.* 2013;28(2):352-359. <https://doi.org/10.1093/ndt/gfs460>
52. Fernandez-Perez L, Guerra B, Diaz-Chico JC, Flores-Morales A. Estrogens regulate the hepatic effects of growth hormone, a hormonal interplay with multiple fates. *Front Endocrinol (Lausanne).* 2013;4:66. <https://doi.org/10.3389/fendo.2013.00066>
53. Huang DS, O'Sullivan AJ. Short-term oral oestrogen therapy dissociates the growth hormone/insulin-like growth factor-I axis without altering energy metabolism in premenopausal women. *Growth Horm IGF Res.* 2009;19(2):162-167. <https://doi.org/10.1016/j.ghir.2008.08.009>
54. Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. *Endocr Rev.* 2004;25(5):693-721. <https://doi.org/10.1210/er.2003-0035>
55. Wolf I, Stein D, Shahmoon S, et al. Alteration in serum klotho levels in anorexia nervosa patients. *Clin Nutr.* 2016;35(4):958-962. <https://doi.org/10.1016/j.clnu.2015.07.013>
56. Oswiecimska JM, Pys-Spychala M, Swietochowska E, et al. Serum alpha-klotho concentrations in girls with anorexia nervosa. *Neuro Endocrinol Lett.* 2015;36(6):539-544.